Serodus merges with Phlogo, inherits first-in-class products
This article was originally published in Scrip
Executive Summary
Danish peptide specialist Phlogo is to merge with a Norwegian biomedical company Serodus, which develops drugs for cardiovascular diseases, after plans received the go-ahead from Serodus shareholders on 10 July.